Storia in 7 fonti

FDA green lights Priovant drug for rare skin disease

Lisraya’s clearance marks the first approval of a drug the Roivant subsidiary licensed from Pfizer and has since positioned against multiple rare inflammatory conditions.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo2 g fa

FDA green lights Priovant drug for rare skin disease

Lisraya’s clearance marks the first approval of a drug the Roivant subsidiary licensed from Pfizer and has since positioned against multiple rare inflammatory conditions.

originale

Timeline cronologica

giovedì 27 agosto 2026·medpagetoday.com
First Oral Option for Dermatomyositis Gets FDA Green Light
Brepocitinib significantly improved overall symptom status in a phase III trial
giovedì 27 agosto 2026·statnews.com
FDA approves Roivant therapy for rare autoimmune disease
The FDA approved a new medicine from Roivant and its subsidiary Priovant for the treatment of dermatomyositis, a rare autoimmune disease.

FDA green lights Priovant drug for rare skin disease

Confronto fonti

FDA green lights Priovant drug for rare skin disease

Timeline cronologica

First Oral Option for Dermatomyositis Gets FDA Green Light

FDA approves Roivant therapy for rare autoimmune disease

FDA approves Lisraya as first oral drug for dermatomyositis

Roivant’s road to a potential blockbuster begins with Lisraya FDA approval

Priovant pushes ex-Pfizer asset across FDA finish line in rare skin and muscle disease

FDA approves Roivant therapy for rare autoimmune disease

Orsini to Serve as Specialty Pharmacy Partner for Priovant's LISRAYA™ (brepocitinib)

Roivant’s road to a potential blockbuster begins with Lisraya FDA approval

FDA approves Lisraya as first oral drug for dermatomyositis

FDA green lights Priovant drug for rare skin disease

Priovant pushes ex-Pfizer asset across FDA finish line in rare skin and muscle disease

Orsini to Serve as Specialty Pharmacy Partner for Priovant's LISRAYA™ (brepocitinib)